PD-1 inhibitors can prevent the interaction of PD-1 with its ligands PD-L1 on tumor cells and inflammatory cells by binding to PD-1, leading to the restoration of antitumor activity of functionally depleted T cells. The gene discussed is PDCD1; the disease is neoplasm.